AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03123757 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: EQ-5D Survey
Description: The EQ-5D is a self-reported questionnaire that describes a respondent's health using a descriptive system comprised of five items, each representing a different health dimension (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). For each dimension, respondents state whether they have no problems, slight problems, moderate problems, severe problems, or are unable to perform the activity.
Study NCT03123757 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Short Physical Performance Battery
Description: The SPPB is a brief performance battery based on timed short distance walk, repeated chair stands and balance test administered by trained examiners. The measurement goal for this battery is to assess lower extremity functional limitations, which indicate functional abilities and are a strong measure of risk for future disability.
Study NCT01714739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lirilumab
Description: Specified dose on specified days.
Study NCT01714739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days.
Study NCT01714739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Specified dose on specified days.
Study NCT02052791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nusinersen
Description: Administered by intrathecal (IT) injection
Study NCT01525654 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Peer Support Program
Description: Partners, are interested in having a support person to talk with while others. Coaches initiate contact, usually via phone but can use email or face to face, with their Partner. During this initial contact, partners determine how often to speak up to a total of 6 months. Peer Support discussions focus on sharing information, education, support related to living with RA.
Study NCT02538835 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Metacognitive therapy
Description: Group format, 10-12 participants in each group. 8 weekly sessions of two hours each.
Study NCT02538835 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness based cognitive therapy, group
Description: Group format, 10-12 participants in each group. 8 weekly sessions of two hours each following the manual described by Williams, Zindel \& Segal.
Study NCT02538835 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Support groups
Description: Group format, 10-12 participants in each group. The sessions will only be of supportive character and will not focus on changing or restructuring thoughts, scripts or thought patterns. The format will follow a manual but compared to the other intervention groups the format allow participants to suggests themes for discussions.
Study NCT02866240 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cathodal Transcranial Direct Current Stimulation (tDCS).
Description: Transcranial direct current stimulation (tDCS) is a form of neurostimulation which uses constant, low current delivered to the brain area of interest via electrodes on the scalp.
Study NCT01270490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon-gamma, Recombinant
Description: Interferon 50 mcg/m2 to be administered three times per week during two weeks
Study NCT01697319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMN 110
Description: Drug will be delivered through a 4 hour (approximate) IV infusion at a dosage amount of 2.0 mg/kg/week for up to 144 weeks of treatment.
Study NCT03720613 — intervention group
Intervention type: DRUG
Intervention: Naldemedine
Description: 0.2 mg tablet once a day at any time with or without food
Study NCT03720613 — intervention group
Intervention type: DRUG
Intervention: Lubiprostone
Description: 0.024 mg twice a day \[adjust dose based on liver function\]
Study NCT03720613 — intervention group
Intervention type: DRUG
Intervention: Naloxegol
Description: 25 mg tablet once a day in morning, 1 hour before or 2 hours after food
Study NCT00132119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nalmefene HCl
Description: Nalmefene HCl film-coated tablets, 20 or 40 mg, administered orally once daily for 10 weeks.
Study NCT06749977 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remineralization with SAP11-4
Description: The WSL were treated with SAP11-4 according to the manufacturer's instruction
Study NCT06749977 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remineralization with sodium fluoride varnish
Description: The WSL were treated with sodium fluoride varnish according to the manufacturer's instruction
Study NCT00132119 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet
Study NCT02177318 — intervention group
Intervention type: DRUG
Intervention: Spiriva (tiotropium bromide) inhalation capsules
Description: Survey of patients with COPD using Spiriva (tiotropium bromide) inhalation capsules
Study NCT01940003 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aquatic exercise
Description: The aquatic exercise program will be under the professional guidance of a physiotherapist, with water at a temperature of around 26 to 28°C. The exercise sessions will be executed following the steps: 1) Heating (stretching and flexibility, static method, during 5'); 2) Aerobic exercise (running, displacements and combined movements of arms and legs, with 1minute interval, to 1minute activity and of during 20') 3) Spot exercises (strength / endurance of the upper and lower limbs and abdomen, using the resistance of water for 15') 4) Relaxation (slow walks for 5'). During the sessions of exercises the pregnant women will have heart rate monitored by the frequency meter (Polar Electro OY) to control the intensity of the exercises that will focus on the range of moderate intensity.
Study NCT03301454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pursuit of chemotherapy
Description: Treatment with LV5FU2 (5-FU, Calcium Levofolinate) - paclitaxel, regular tumor evaluation, best supportive care Other authorized treatment : usual paclitaxel pre-treatment consisting of Dexamethasone, Chlorpheniramine and ranitidine, at 15 and 1 day before the actual paclitaxel treatment
Study NCT00924534 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00924534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLV337
Description: SLV337 400 mg/day
Study NCT00924534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLV337
Description: SLV337 800 mg/day
Study NCT00924534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLV337
Description: SLV337 1400 mg/day
Study NCT00303836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV
Study NCT00303836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Given IV
Study NCT00303836 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: therapeutic autologous lymphocytes
Description: Given IV
Study NCT00303836 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: in vitro-treated peripheral blood stem cell transplantation
Description: Undergo in vitro-treated peripheral blood stem cell transplantation
Study NCT00303836 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: gp100 antigen
Description: Given SC
Study NCT00303836 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MART-1 antigen
Description: Given SC
Study NCT00303836 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: incomplete Freund's adjuvant
Description: Given SC
Study NCT00303836 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given SC
Study NCT00303836 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aldesleukin
Description: Given IV
Study NCT02770430 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mesenchymal stem cells
Description: MSCs derived from bone marrow (BM) will be isolated and expanded in the laboratory under conditions of Good Manufacturing Practice. The quality control involves immunophenotyping, differentiation, microbiological control, mycoplasma and endotoxin tests. Patients will receive five infusions of MSC. Dosage: 2x10E6 cells/Kg
Study NCT02770430 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: conventional treatment
Description: 1. Basiliximab 20mg dose for adults and 10mg for children, 1 time a week or every 3 days if worsens the stage of GVHD until reaching Very Good Partial Response (VGPR) or for a maximum of 4 doses, whichever comes first.~2. If after the item (1) will not obtained VGPR: Infliximab 5 to 10 mg/kg dose, 1 time a week, four weeks or even VGPR.
Study NCT01712113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irbesartan
Study NCT01712113 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Avapro
Study NCT00476060 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous mesenchymal stem cell transplantation
Description: Arm A: 300 million cells will be infused one time through a peripheral vein/// Arm B: Infusion of placebo one time through a peripheral vein
Study NCT00476060 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Autologous mesenchymal stem cell transplantation
Description: Arm A: 300 million cells will be infused one time through a peripheral vein/// Arm B: Infusion of placebo one time through a peripheral vein
Study NCT03795558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etelcalcetide
Description: Up-Titration
Study NCT03008915 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: 81mg aspirin taken once per day in the morning
Study NCT03008915 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aspirin
Description: 81mg aspirin taken once per day in the morning
Study NCT03008915 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: placebo taken once per day in the morning
Study NCT03008915 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo taken once per day in the morning
Study NCT03008915 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Withdrawal from alpha1 antitrypsin replacement therapy
Description: After the completion of the randomization to aspirin and placebo, participants who are on alpha1 replacement therapy are asked to withhold their usual alpha1 antitrypsin replacement therapy for 5 weeks. This is not randomized.
Study NCT03008915 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Withdrawal from alpha1 antitrypsin replacement therapy
Description: After the completion of the randomization to aspirin and placebo, participants who are on alpha1 replacement therapy are asked to withhold their usual alpha1 antitrypsin replacement therapy for 5 weeks. This is not randomized.
Study NCT01376336 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Safe storage device
Description: This device is a specially designed water storage container that is intended to reduce the likelihood of re-contamination of household stored drinking water.
Study NCT00794118 — intervention group
Intervention type: OTHER
Intervention: As per clinical practice
Description: As per clinical practice
Study NCT00174707 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: epidoxorubicine, ciclophosphamide, methotrexate, fluorouracile
Description: Sequential Epidoxorubicin followed by ciclophosphamide/Methotrexate/fluorouracile (±TAM)
Study NCT00174707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epidoxorubicine, docetaxel, ciclophosphamide, methotrexate, fluorouracile
Description: Sequential Epidoxorubicin followed by Docetaxel followed by ciclophosphamide/methotrexate/fluorouracile (± TAM)
Study NCT00174707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epidoxorubicine, docetaxel, cyclophosphamide
Description: Sequential Intensified Epidoxorubicin followed by Docetaxel followed by Cyclophosphamide (± TAM)
Study NCT02128620 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Game-Based Appointment System
Description: Users randomized to the www.sjekkdeg.no B version, consisting in the web app www.sjekkdeg.no including the Game-Based Appointment System
Study NCT01240811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IUD placement
Description: Volunteer subjects who are not at risk of pregnancy because they are either surgically sterilized or heterosexually abstinent will be enrolled into the control group (no intervention). All other volunteers will be seeking an IUD for contraception and will be randomized to LNG-IUD (Mirena) or Copper IUD (ParaGard).
Study NCT01240811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levonorgestrel IUD
Study NCT01240811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copper T380A IUD
Study NCT03108144 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief alcohol intervention
Description: The intervention is a clinical decision support system (CDSS) that provides a computerized prompt in the clinic's online portal. The CDSS prompts a practitioner to intervene when a patient is screening above recommended drinking guidelines. The prompt appears as an alert message, recommending intervention. The portal suggests scripted brief intervention language, designed based on the College of Family Physicians of Canada and Canadian Centre on Substance Abuse's resource on conducting evidence-based Screening, Brief Intervention, and Referral to Treatment (SBIRT) guidelines.
Study NCT01554540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cutaneous iontophoresis of treprostinil
Description: Cutaneous iontophoresis of treprostinil 0.1mg/ml, on the forearm and the fingers. (charge 40-240 mC).
Study NCT01554540 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cutaneous iontophoresis of treprostinil
Description: Cutaneous iontophoresis of treprostinil 0.1mg/ml, on the forearm and the fingers. (charge 40-240 mC).
Study NCT04243135 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ESWT
Description: Extracorporeal shock wave therapy
Study NCT04243135 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: ESWT
Description: Extracorporeal shock wave therapy
Study NCT02478541 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sugar study
Description: Subjects are given a single test meal on two study days that has a sugary drink that varies in the amount of fructose and glucose it contains. They consume the same amount of fat on both study days.
Study NCT00882726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTO 3649 IV (Healthy participants)
Description: Healthy participants will each receive a single dose of CNTO 3649 (1, 3, 10, 30, 100 or 300 microgram per kilogram, subject to change) as a 2-hour IV infusion.
Study NCT00882726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTO 3649 SC (Healthy participants)
Description: Healthy participants will each receive a single dose of CNTO 3649 (10, 30, 100 or 300 microgram per kilogram, subject to change) as a SC injection.
Study NCT04057248 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dario Blood Glucose Monitoring System
Description: Dario Blood Glucose Monitoring System (BGMS) with Dario App and Dario digital platform
Study NCT04057248 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CDE
Description: Certified Diabetes Educator Sessions
Study NCT00922324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STP206 or vehicle control
Description: STP206 or vehicle administered as either a single dose or as a daily dose for 7 consecutive days
Study NCT00922324 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: STP206 or vehicle control
Description: STP206 or vehicle administered as either a single dose or as a daily dose for 7 consecutive days
Study NCT00882726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTO 3649 SC (Diabetic patients)
Description: Diabetic patients will receive multiple doses of CNTO 3649 (30, 100 or 300 microgram per kilogram, subject to change) as subcutaneous injections once weekly for 4 consecutive weeks.
Study NCT00882726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants within each dosing group who are randomized to placebo will receive a corresponding IV infusion or SC injection of placebo.
Study NCT04068467 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smartphone App
Description: The application consists of content areas focused on mental health.
Study NCT04068467 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Waitlist Control
Description: Waitlist control
Study NCT00300300 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computer-assisted surgery
Description: no description
Study NCT01263210 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevenar
Study NCT00171340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Description: Zolendronic acid 4 mg Intravenous (IV) 15 minute infusion every 6 months.
Study NCT03514134 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality Job Interview Training
Description: Students will engage in didactic training related to strategies to perform well during a job interview as well as repeated practice with a virtual hiring manager. Throughout and after completion of the virtual interviews, participants will receive feedback on their performance.
Study NCT00922675 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Postconditioning
Description: After opening of IRA and establishment of TIMI-flow grade 2 or 3, the control group continues the procedure with stenting. In the postconditioning group 4 additional balloon inflations separated by 1 minute reperfusion are given, starting after 1 minute of reperfusion.
Study NCT00922675 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Control intervention
Description: After opening of IRA and establishment of TIMI-flow grade 2 or 3, the control group continues the procedure with stenting.
Study NCT05076656 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus fermentum D3
Description: Lactobacillus fermentum D3 in a white, gelatin capsule (orally), with lyophilized L. fermentum D3 without preservatives, sugars, or additives.
Study NCT05076656 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplant (FMT)
Description: Fecal microbiota transplant (FMT) in a green, gelatin capsule (orally), with lyophilized fecal material.
Study NCT05076656 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo in a white, gelatin capsule (orally), with powder milk
Study NCT02207075 — intervention group
Intervention type: DRUG
Intervention: [C11]PK-1195 PET scan
Description: PET scan with tracer \[C11\]PK-1195
Study NCT00187239 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Autointrinsic Conduction Search Algorithm
Description: Autointrinsic conduction search is programmed on in those patients randomized to AICS ON.
Study NCT02196038 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: multi-domain rehabilitation intervention
Description: Individual, tailored, progressive physical function rehabilitation intervention
Study NCT02196038 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Attention Control
Description: Usual care with bi-weekly contact from study staff
Study NCT01913249 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LIFT
Description: Ligation of intersphincteric fistula tract
Study NCT01913249 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LIFT
Description: Ligation of intersphincteric fistula tract
Study NCT03226080 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium
Description: The neuromuscular blockade group will receive intravenous rocuronium
Study NCT03226080 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugammadex
Description: The neuromuscular blockade group will receive intravenous sugammadex for reversal of residual rocuronium
Study NCT03226080 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline will be administered as a placebo in equal volume for the placebo group
Study NCT00516269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Description: 18 mg by mouth daily for 2 weeks
Study NCT00516269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Capsule by mouth daily for 2 weeks
Study NCT01468909 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01468909 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01468909 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: Given IV
Study NCT01468909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study NCT01468909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib Hydrochloride
Description: Given PO
Study NCT01468909 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given PO